Exviera, Viekirax
Petr Urbánek Orcid.org 1
+ Affiliation
To read this article in full, please register for free on this website.
Benefits for subscribers
Benefits for logged users
Literature
1. Němeček V. Sérologický přehled ČR v roce 2001 – virová hepatitida A, B, C. Zprávy CEM 003; 12: 55– 61.
2. World Health Organization. Global alert and response (GAR). Hepatitis C. [online]. Available from: http:/ / www.who.int/ csr/ disease/ hepatitis/ whocdscsrlyo2003/ en/ .
3. Perz JF, Armstrong GL, Farrington LA et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45(4): 529– 538.
4. Kanwal F, Hoang T, Kramer JR et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011; 140(4): 1182– 1188. doi: 10.1053/ j.gastro.2010.12.032.
5. Urbánek P, Husa P, Galský J et al. Standardní diagnostický a terapeutický postup chronické infekce virem hepatitidy C (HCV). Čas Lék Čes 2008; 147(5): příloha: I– XII.
6. Fried MW, Shiffman ML, Reddy KR et al.
Peginterferon alfa‑2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347(13): 975– 982.
7. Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon‑alfa2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140(5): 346– 355.
8. Urbánek P. Novinky v terapii chronické infekce virem hepatitidy C. Remedia 2011, 21: 380– 385.
9. Urbánek P, Husa P, Galský J et al. Standardní diagnostický a terapeutický postup u chronické infekce virem hepatitidy C (HCV). Gastroent Hepatol 2012; 66(3): 214– 229.
10. Viekirax SPC. North Chicago, IL: AbbVie 2014.
11. Feld JJ, Kowdley KV, Coakley E et al. Treatment of HCV with ABT‑ 450/ r‑ ombitasvir and dasabuvir with ribavirin.
N Engl J Med 2014; 370(17):1594– 1603. doi: 10.1056/ NEJMoa1315722.
12. Zeuzem S, Jacobson IM, Baykal T et al. Retreatment of HCV with ABT‑ 450/ r‑ ombitasvir and dasabuvir with ribavirin.
N Engl J Med 2014; 370(17): 1604– 1614. doi: 10.1056/ NEJMoa1401561.
13. Poordad F, Hezode C, Trinh R et al. ABT‑ 450/ r‑ ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
N Engl J Med 2014; 370(21): 1973– 1982. doi: 10.1056/ NEJMoa1402869.
14. Manns MP, Foster GR, Rockstroh JK et al. The way forward in HCV treatment – finding the right path. Nat Rev Drug Discov 2007; 6(12): 991–1000.